Detection of Human Immunodeficiency Virus Core Protein in Plasma by Enzyme Immunoassay

Association of Antigenemia with Symptomatic Disease and T-Helper Cell Depletion

  1. ALEC E. WITTEK, M.D., C.M.;
  2. MICHAEL A. PHELAN, Ph.D.;
  3. MARTHA A. WELLS, B.S.;
  4. LUBA K. VUJCIC, M.S.;
  5. JAY S. EPSTEIN, M.D.;
  6. H. CLIFFORD LANE, M.D.; and
  7. GERALD V. QUINNAN, Jr., M.D.
  1. Bethesda, Maryland

    Abstract

    A sensitive enzyme immunoassay was developed for detecting human immunodeficiency virus (HIV) core antigen. Assay sensitivity was 3.67 pmol/L of purified HIV core protein, and 1 or 100 in-vitro infectious units/mL of HIV in purified virus preparations or cell culture supernatants, respectively. Enzyme immunoassay sensitivity exceeded that of reverse transcriptase assay by 1000-fold. Core antigen was detected in whole plasma from 41% of symptomatic subjects and 13% of asymptomatic subjects seropositive for HIV. After plasma fractionation, antigenemia was found in 60% of symptomatic subjects and in 33% of asymptomatic subjects seropositive for HIV. Fifty-seven percent of samples from which HIV could be isolated in lymphocyte culture had detectable quantities of core antigen in plasma. However, at least 87% of samples with measurable antigen in plasma had HIV isolated from lymphocyte cultures. Antigenemia was associated with reduced T-cell number and symptomatic disease, and may be a useful marker for disease progression.

    Article and Author Information

    • ▸From the Division of Virology, Office of Biologics Research and Review, Food and Drug Administration, and Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases; Bethesda, Maryland.

    • ▸Requests for reprints should be addressed to Alec E. Wittek, M.D.; Division of virology, HFN-840, Office of Biologics Research and Review, 8800 Rockville Pike; Bethesda, MD 20892.

    « Previous | Next Article »Table of Contents